INTRODUCTION

Toluene diisocyanate (TDI) is a very common cause of occupational asthma (OA) worldwide. The pathogenic mechanisms of TDI-induced asthma are more variable than those of atopic and non-atopic asthma. However, similar to non-OA, OA may result from the complicated interactions of multiple genetic and environmental factors. Genetic factors may modify TDI-induced asthma susceptibility, as seen in previous studies in which only 5–15% of isocyanate-exposed workers developed asthma. The genes for glutathione S-transferase (GSTP1 and GSTM1), N-acetyltransferase (NAT), HLA classes I and II, and neurokinin 2 receptor (NK2R) may all confer susceptibility to or protection against TDI exposure-associated asthma. β2-adrenergic receptor gene (ADRB2) polymorphisms have been identified, which are functionally relevant and may modify disease; numerous clinical studies have described the effects of such polymorphisms on asthma and related phenotypes. The ADRB2 is a small, intronless gene that has recently been resequenced in multiple ethnic populations to determine polymorphic variability and haplotype structure. Two ADRB2 single nucleotide polymorphisms (SNPs) at codons 16 and 27 are frequently associated with the asthmatic phenotype; the Gly16 variant is positively associated with severe and nocturnal asthma. Isocyanates may act as pharmacological inhibitors of β2-adrenergic receptor.
tors in TDI-OA by affecting the ability to produce cyclic adenosine monophosphate and to maintain bronchial tone.\textsuperscript{14,15} A previous study established that β\textsubscript{2}-adrenergic receptor stimulation inhibited release of proinflammatory mediators from mast cells and influenced T-cell growth and function as well as eosinophil survival and function.\textsuperscript{16} Therefore, many lung cell types implicated in asthma pathogenesis are potentially influenced by β\textsubscript{2}-adrenergic receptor signals. Previous studies have identified pharmacoethnic differences between Korean and Caucasian populations in the ADBR2 genotype distribution and the pharcogenetic association of responses to β\textsubscript{2}-agonists.\textsuperscript{17-19}

No studies to date have evaluated ADBR2 polymorphisms as possible disease modifiers in TDI-OA. To our knowledge, this is the first investigation to evaluate the genetic association of ADBR2 polymorphisms with the TDI-OA phenotype in a Korean population.

**MATERIALS AND METHODS**

**Subjects**

Patients with confirmed TDI-OA (n=103) were included in the study. Patients were primarily diagnosed by positive responses to TDI bronchoprovocation tests. TDI-exposed asymptomatic workers (n=60) were enrolled from work environments with similar intensities of TDI exposure (spray painters, furniture polishers, and musical instrument factory workers) and comprised the asymptomatically exposed control group (AEC). A total of 263 unexposed healthy control subjects (NC) were recruited from the volunteer population. All subjects provided informed consent and the study was approved by the Institutional Review Board of Ajou Medical Center, Suwon, Korea.

The demographic data for the three study groups are summarized in Table 1. Atopy was determined by a positive skin test to at least one common inhalant allergen. The battery of allergens included the house dust mite, tree and pollen mixtures, mugwort, ragweed pollens, and alternaria (Bencard, Worthing, West Sussex, UK). Serum samples from TDI-OA individuals were collected at initial diagnosis during the exposure period; all participants discontinued inhaled or oral steroids 4 weeks prior to the start of the study. Participants in the TDI-OA and NC groups underwent an interview, chest radiography, and skin prick test with common inhalant allergens. Pulmonary function measurements and methacholine inhalation challenge were performed in TDI-OA subjects.

**Bronchial challenge test with methacholine and TDI**

The methacholine bronchial challenge test was performed in TDI-OA patients as described previously.\textsuperscript{20} Briefly, aerosols were generated with a DeVilbiss 646 nebulizer connected to a DeVilbiss dosimeter driven by compressed air (DeVilbiss Co., Doylestown, PA, USA). Normal saline inhalation at 5-minutes intervals was followed by a series of progressively increasing doses of methacholine (0.075–25 mg/mL) until a 20% fall in forced expiratory volume in the first second (FEV\textsubscript{1}) was observed or until the maximum dosage was reached. FEV\textsubscript{1} was measured 5 minutes after the initiation of each set of aerosolized methacholine inhalation. The methacholine concentration resulting in a 20% fall in FEV\textsubscript{1} (PC\textsubscript{20}) was determined by interpolation from the dose-response curve. The TDI bronchial challenge test was performed according to the procedure described previously.\textsuperscript{20}

**Table 1. Clinical characteristics of the study subjects**

| Parameter                        | TDI-OA (n=103) | AEC (n=60) | NC (n=263) |
|----------------------------------|----------------|------------|------------|
| Age (yr)*                        | 41.3±9.8       | 41.7±7.6   | 34.1±14.3  |
| Sex (male/female)*              | 69/34          | 45/15      | 96/167     |
| Atopy*                          | 35/75 (46.7%)  | NA         | 33/192 (17.2%) |
| Exposure duration (yr)*         | 7.1±4.9        | 12.0±7.3   | NA         |
| FEV\textsubscript{1} (%)        | 85.7±20.4      | 90.2±20.2  | NA         |
| PC\textsubscript{20} methacholine (mg/mL) | 4.9±7.9       | NA         | NA         |
| Serum total IgE (IU/mL)*        | 284.8±4346.7   | 265.7±584.9 | 102.3±167.6 |
| Specific IgG to TDI-HSA          | 17/70 (24.3%)  | 7/60 (11.7%) | NA         |
| Specific IgE to TDI-HSA*         | 19/70 (27.1%)  | 4/60 (6.7%)  | NA         |

Results are expressed as the mean±SD.

FEV\textsubscript{1} and PC\textsubscript{20} were measured at initial diagnosis.* P<0.01, for TDI vs. NC; †P<0.01, for TDI vs. AEC.

**Specific IgG and IgE antibodies to TDI–HSA conjugate determined by ELISA**

The vapor-type TDI-human serum albumin (HSA) conjugate was prepared from 80% 2,4-TDI isomers based on the recently described isocyanate vapor-phase exposure system.\textsuperscript{21,22} Serum-specific IgE and IgG levels were determined by enzyme-linked immunosorbent assay (ELISA), as described previously.\textsuperscript{23} Briefly, TDI-albumin conjugate (1 μg) or mock conjugate was dissolved in normal saline and used to coat ELISA plates (Corning, New York, NY, USA) at 37°C for 2 hours, followed by overnight incubation at 4°C. Plates were washed with PBS-Tween 20 (PBS-T), and blocked with blocking buffer (350 μL, PBS containing 5% BSA and 0.05% Tween 20). Sera from patients and control subjects were diluted 1:5 for specific IgG measurements and at 1:3 for specific IgE; sera (50 μL) were incubated in TDI-albumin- and mock albumin-coated wells for 1 hour at 25°C. Plates were washed four times, and alkaline phosphatase-conjugated anti-IgG antibody (1:20,000, 100 μL; Sigma, St. Louis, MO, USA) or goat anti-IgE (1:1,000; Kirkegaard and Perry Laboratories, Gaithersburg, MD, USA) and alkaline phosphatase-conjugated rabbit anti-goat IgG antibody (1:200; Kirkegaard and Perry Lab-
Statistical analysis

The ADRB2 gene fragment containing the promoter and exon 1 (1,483 bp) was sequenced to examine SNPs in DNA samples from subjects. DNA sequencing was performed using an ABI Prism 3100 DNA analyzer (Applied Biosystems, Foster City, CA, USA). Primers (5’-CCTAAAGTCTGTGCACATAAC-3’ and 5’-GCCCTCAGATTTGTCAATCTTC-3’) were designed for amplification and sequencing. The PCR mix (30 μL) contained primers (10 pmol), dNTPs (1 μM), and Taq DNA polymerase (1 U). The amplification program included a single cycle at 94°C for 5 minutes followed by 35 cycles of 94°C for 30 seconds, 60°C for 40 seconds, and 72°C for 90 seconds, with a final extension at 72°C for 7 minutes. Sequence variants were identified on chromatograms, which detected six SNPs (–47 T>C, –20 T>C, Arg16Gly A>G, Gln27Glu C>G, Leu134Leu G>A, and Arg175Arg). The SNP genotypes were verified by direct sequencing of the PCR products.

Statistical analysis

The chi-square (χ²) test with one degree of freedom (df) was used to test the frequency of each SNP for significant departure from Hardy-Weinberg equilibrium. Differences in genotypic frequency between patients or exposed and control subjects were examined by the χ² test. To evaluate the genetic associations among the TDI-OA, AEC, and NC groups, logistic regression models (codominant, dominant, and recessive) were used to analyze SNPs and haplotypes after controlling for age and gender as covariates. Subject haplotypes from ADRB2 polymorphisms were estimated using the hapassoc package in R 2.9.0,23 based on an estimation-maximization algorithm (EM). Linkage disequilibrium between loci was measured with the logarithm of odds (LOD) score. Logistic regression controlling for age and gender as covariates was applied to predict the genetic effects of ADRB2 haplotypes for IgE sensitization to TDI-HSA conjugate using the null haplotype as the reference. The P-values were corrected by false discovery rate (FDR, R2.7.1; R foundation for Statistical Computing, Vienna, Austria), which is a statistical means to correct for confounding effects of multiple genetic and clinical factors. Associations are expressed as adjusted logistic odds ratio (OR) and 95% confidence intervals (95% CI). Student’s t test was used to compare continuous variables (values are expressed as means±standard deviation [SD]). Categorical variables were compared using the χ² test or Fisher’s exact test. Continuous variables without a normal distribution were log-transformed and presented on their original scale. Statistical analyses were performed with SPSS ver. 12.0.1 (SPSS Inc., Chicago, IL, USA). In all analyses, P<0.05 was taken to indicate statistical significance.

RESULTS

Demographics of the study population

The demographic data of TDI-OA patients (n=103), AEC individuals (n=60), and unexposed healthy controls (NC; n=263) are shown in Table 1. There were no significant differences in mean age, gender distribution, or serum total IgE levels between the TDI-OA and AEC groups. Exposure durations were significantly longer in the AEC group than in the TDI-OA group. Methacholine challenge testing was not performed in participants in the AEC and NC groups because these healthy individuals reported no respiratory symptoms.

Allele, genotype, and haplotype frequencies of the beta 2-adrenergic receptor gene

A genetic association study of six SNPs (–47 T>C, –20 T>C, Arg16Gly A>G, Gln27Glu C>G, Leu134Leu G>A, and Arg175Arg C>A) was performed in the three study groups (Table 2). The allele and genotype frequencies were consistent with previous studies in Korean populations.24,25 There were no significant differences in allelic, genotypic, or haplotypic frequencies of the six SNPs among the study groups. The six SNPs of ADBR2 polymorphisms were in linkage disequilibrium (LOD score >3, Figure); four haplotypes including hт1 [TTACGC], hт2 [TTGCAA], hт3 [CCGGGC], and hт4 [TTGCGC] were constructed with the EM

Figure. Linkage disequilibrium plot of ADRB2 6 polymorphisms using the confidence bounds color scheme of Haploview 3.32. Dark grey, light grey, and white blocks indicate strong evidence for linkage disequilibrium, uninformative, and strong evidence for recombination, respectively.
algorithm, but both ht3 and ht4 had a frequency of less than 5%. There were no significant differences in genotype distributions of the four ADRB2 haplotypes among the three groups (Table 2).

**Effects of ADRB2 polymorphisms on the clinical parameters in patients with TDI exposure**

We compared the clinical parameters in TDI-exposed subjects (TDI-OA and AEC groups) according to the six ADRB2 SNPs to assess the relationship between ADRB2 polymorphisms and the TDI-OA phenotype (Table 3). There were no significant differences in asthma duration, baseline FEV1, PC20, or total serum IgE levels among the genotypes of the six SNPs (data not shown). Among the three analysis models (codominant, dominant, and recessive models), the ADRB2, Arg16Gly, Leu134Leu, and Arg173Arg polymorphisms showed highly significant effects on the prevalence of serum specific IgE to the TDI-HSA conjugate, with the highest significance observed in the codominant model (OR, 3.09; 95% CI, 1.47–6.51 for Arg16Gly A>G, OR, 2.42; 95% CI, 1.16–5.07 for Leu134Leu G>A and OR, 2.97; 95% CI, 1.39–6.32 for Arg173Arg C>A) (Table 3). Of the six SNPs, only the Arg16Gly A>G polymorphism had a significant association with IgE sensitization to the TDI-HSA conjugate under all three modes of inheritance. This effect was significant after correction for multiple hypothesis testing ($P = 0.038$ for the codominant model, $P = 0.041$ for the dominant model, and $P = 0.050$ for the recessive model).
for the recessive model). Homozygous ADRB2 ht1/ht1 showed a significantly higher prevalence of specific IgE to TDI-HSA conjugate compared with the null ht1 (P=0.048; OR, 15.40; 95% CI, 1.81–131.06; Table 3). However, the ADRB2 ht2 haplotype was not significantly associated with IgE sensitization to the TDI-HSA conjugate in this study. The statistical power (type I error=0.05) for evaluating the specific IgE to TDI-HSA conjugate association with genetic polymorphisms (ADRB2 Arg16Gly A>G and Arg175Arg C>A and haplotypes ht1[TTACGC] and ht2[TTGCAA]) in TDI-exposed workers, including both TDI-induced asthma patients and asymptomatic exposed controls (n=130).

Table 3. Comparison of the prevalence of specific IgE antibodies to TDI-HSA conjugates stratified by the genotypes ADRB2 Arg16Gly A>G, Leu134Leu G>A, Arg175Arg C>A and haplotypes ht1[TTACGC] and ht2[TTGCAA] in TDI-exposed workers, including both TDI-induced asthma patients and asymptomatic exposed controls (n=130).

| Loci    | Genotype/ Haplotype | IgE to TDI-HSA Positive (n=23) (%) | Negative (n=107) (%) | Pvalue* | OR (95% CI) | Pc† |
|---------|---------------------|-----------------------------------|----------------------|---------|-------------|-----|
| -47 T>C | TT                  | 23 (100)                          | 96 (93.2)            | 0.999   | NA          | 0.999|
|         | TC                  | 0                                 | 7 (6.8)              |         |             |     |
|         | CC                  | 0                                 | 0                    |         |             |     |
| -20 T>C | TT                  | 23 (100)                          | 97 (94.2)            | 0.999   | NA          | 0.999|
|         | TC                  | 0                                 | 6 (5.8)              |         |             |     |
|         | CC                  | 0                                 | 0                    |         |             |     |
| Arg16Gly A>G | AA                | 11 (47.8)                         | 22 (20.8)            | 0.003   | 3.09 (1.47-6.51) | 0.038|
|         | AG                  | 11 (47.8)                         | 55 (51.9)            | 0.038   | 2.97 (1.06-8.32) | 0.095|
|         | GG                  | 1 (4.3)                           | 29 (27.4)            | 0.011   | 1.86 (1.15-2.99) | 0.041|
| Gln27Glu C>G | CC                | 23 (100)                          | 99 (94.3)            | 0.999   | NA          | 0.999|
|         | CG                  | 0                                 | 6 (5.7)              | 0.999   |             |     |
|         | GG                  | 0                                 | 0                    | 0.999   |             |     |
| Leu134Leu G>A | GG                | 12 (52.2)                         | 31 (30.1)            | 0.019   | 2.42 (1.16-5.07) | 0.057|
|         | AG                  | 10 (43.5)                         | 51 (49.5)            | 0.086   | 2.48 (1.08-5.72) | 0.143|
|         | AA                  | 1 (4.3)                           | 21 (20.4)            | 0.047   | 1.60 (1.01-2.56) | 0.101|
| Arg175Arg C>A | CC                | 13 (56.5)                         | 29 (28.2)            | 0.006   | 2.97 (1.39-6.32) | 0.038|
|         | AC                  | 9 (39.1)                          | 51 (49.5)            | 0.056   | 2.76 (0.97-8.23) | 0.095|
|         | AA                  | 1 (4.3)                           | 23 (22.3)            | 0.011   | 1.85 (1.15-2.97) | 0.041|
| ht1 [TTACGC] | ht1/ht1            | 10 (43.5)                         | 20 (18.7)            | 0.012   | 15.40 (1.81-131.06) | 0.048|
|         | ht1/-               | 12 (52.2)                         | 57 (53.3)            | 0.078   | 6.60 (0.81-53.73) | 0.087|
|         | -/-                 | 1 (4.3)                           | 30 (28.0)            | R       |             |     |
| ht2 [TTGCAA] | ht2/ht2            | 1 (4.3)                           | 18 (16.8)            | 0.064   | 0.13 (0.02-1.13) | 0.087|
|         | ht2/-               | 9 (39.1)                          | 55 (51.4)            | 0.087   | 0.43 (0.17-1.13) | 0.087|
|         | -/-                 | 13 (56.5)                         | 34 (31.8)            | R       |             |     |

*Each OR (95% CI) for the genetic association of six SNPs was calculated using the co-dominant, dominant, and recessive models. Logistic regression analysis was used to control age and sex as covariates. †Pc was calculated using the False Discovery Rate method to adjust for multiple testing. TDI-HSA, TDI conjugated with human serum albumin; ADRB2, β2-adrenergic receptor gene; n, number of subjects whose serum specific IgE to TDI-HSA was measured; OR, odds ratio; 95% CI, 95% confidence interval; NA, not available; ht1, haplotype 1; ht2, haplotype 2; R, reference genotype.

No significant differences were observed with serum specific IgG antibody.

Homozygotes for the ADRB2 Arg16 allele or haplotype 1 [TTACGC] tended to show lower PC20 methacholine than Gly16 homozygotes among TDI-OA patients (homozygous for Arg16, 3.1±5.3 mg/mL vs. homozygous for Gly16, 9.3±17 mg/mL; P>0.05) in terms of airway hyperresponsiveness assessed by the methacholine bronchial challenge test. However, there was no significant relation between the genotypes or haplotypes of the six ADRB2 SNPs and the degree of airway hyperresponsiveness.

**DISCUSSION**

We screened the genotypic and allelic frequencies of six ADRB2 SNPs, including the two most common sites, Arg16Gly and Gln27Glu, in the present study. We identified significant associations between the frequencies of the Arg16Gly and Arg173Arg SNPs and the ht1 [TTACGC] haplotype and the prevalence of specific IgE antibodies to the TDI-HSA conjugate among TDI-exposed participants. Several genetic factors have recently been identified that may alter OA risk. The present study is the first to investigate a possible association between ADRB2 polymorphi-
ADRB2 Polymorphisms in TDI-Induced Asthma

IgE, resulting in TDI-OA.3,21,22,35 We detected IgE with the 80% ADRB2 genetic polymorphisms in the same population.

The β2-adrenergic receptor is a G protein-coupled receptor that mediates catecholamine actions in multiple human tissues. β2-adrenergic receptors are present on the surface of inflammatory cells and may modulate signaling pathways in these cells. β2-adrenergic receptor stimulation could induce increased IgE production by human B lymphocytes; it may also enhance production and expression of soluble, high-affinity IgE receptor (sCD23), suggesting that this receptor agonist may be involved in IgE synthesis.26 The anti-inflammatory effects of β2-agonists may inhibit the elaboration of mediators from mast cells.27 Several studies have demonstrated that altered β2-adrenergic receptor signaling due to the ADBR2 polymorphisms Arg16Gly and Gln27Glu could potentially affect airway smooth muscle contractility and inflammatory cytokine production, and therefore modulate IgE production through β2-adrenergic receptors expressed on B and T lymphocytes in vitro and in vivo.28-30 A previous study demonstrated that increased adrenergic downregulation was related to the ADRB2 Arg16Gly polymorphism.31 However, other studies have not identified significant associations between the Gly27Glu or Arg16Gly ADRB2 polymorphisms and total serum IgE levels in Korean populations.17,25,32 Llanes et al.33 did not identify significant associations between genetic variations of ADRB2 and sCD23 serum levels in response to skin prick testing with Ascaris lumbricoides in a Venezuelan cohort, although no significant associations were identified between physician-diagnosed asthma and ADRB2 genetic polymorphisms in the same population.

It is generally accepted that TDI exposure can induce specific IgE, resulting in TDI-OA.2,3,21,35 We detected IgE with the 80% vapor-type TDI-HSA conjugate in the present study, and demonstrated a significant association with the ADBR2 Arg16Gly AA/AG genotype and ht1 [TTACGC]; these observations suggested that this genotype could serve as a risk factor for increased specific IgE sensitization in TDI-exposed workers and could ultimately contribute to the development of asthmatic symptoms. However, the mechanism by which the ADRB2 polymorphism induced IgE sensitization to inhaled TDI is still unclear. It is possible that β2-adrenergic receptors on inflammatory cells from subjects with the haplotype 1 [TTACGC] of ADBR2 polymorphisms, and particularly the ADRB2 Arg16Gly AA genotype, are more susceptible to the generation of serum specific IgE antibodies in response to inhaled TDI.

Our study had possible limitations considering the issue of multiple comparisons. The six ADRB2 SNPs evaluated in the present study had moderate levels of linkage disequilibrium and were thus not fully independent tests. In this case, if strict Bonferroni correction was applied to the multiple comparisons for a single genetic polymorphism, false negative rates usually increased. Therefore, an alternative adjustment for multiple hypothesis testing is to use the FDR method, which estimates the likelihood that our findings are false.36 Regardless of FDR adjustments, evidence of significant associations among ADRB2 Arg16Gly, Arg175Arg, and ht1 with the prevalence of specific IgE to TDI-HSA conjugate remain.

OA is a complex disease characterized by multiple genetic and environmental factors. We attempted to reduce environmental effects on the asthma phenotype in the present study by enrolling healthy, asymptomatic exposed controls. After adjusting for age, gender, and other ADRB2 SNPs, the ht1 [TTACGC] haplotype, composed of all wild genotypes of Arg16Gly, Leu134Leu, and Arg175Arg among the six ADRB2 SNPs, was significantly associated with specific IgE sensitization in TDI-exposed workers. Additional environmental factors, including inhaled allergen exposure, smoking, and viral infections, must undergo further evaluation.37 Therefore, further studies are required to evaluate the associations between ADRB2 polymorphisms and TDI-OA pathogenesis and to better elucidate the complex interactions of ADRB2 polymorphisms with environmental or genetic factors that may increase TDI-OA susceptibility. Our results suggest that the ht1 haplotype, which includes all wild genotypes of Arg16Gly, Leu134Leu, and Arg175Arg, may be a risk factor for developing specific IgE sensitization to TDI.

ACKNOWLEDGMENTS

This study was supported by grants from the Korean Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (A07001). The authors would like to thank Adam Wisnewski and Carrie Redlich, Yale School of Medicine, New Haven, CT, USA, for kindly providing the TDI-HSA conjugates and for helpful discussions.

REFERENCES

1. Maestrelli P, Boschetto P, Fabbri LM, Mapp CE. Mechanisms of occupational asthma. J Allergy Clin Immunol 2009;123:531-42; quiz 43-4.
2. Ober C, Thompson EE. Rethinking genetic models of asthma: the role of environmental modifiers. Curr Opin Immunol 2005;17:670-8.
3. Park HS, Cho SH, Hong CS, Kim YV. Isocyanate-induced occupational asthma in far-east Asia: pathogenesis to prognosis. Clin Exp Allergy 2002;32:198-204.
4. Mapp CE, Fryer AA, De Marzo N, Pozzato V, Padoan M, Boschetto P, Strange RC, Hemmingsen A, Spiteri MA. Glutathione S-transferase GST1P1 is a susceptibility gene for occupational asthma induced by isocyanates. J Allergy Clin Immunol 2002;109:867-72.
5. Wikman H, Pirilä P, Rosenberg C, Lunekonen R, Kääriä K, Nordman
H, Norppa H, Vainio H, Hirvonen A. N-Acetyltransferase genotypes as modifiers of diisocyanate exposure-associated asthma risk. Pharmacogenetics 2002;12:227–33.

6. Choi JH, Lee KW, Kim CW, Park CS, Lee HY, Hur GY, Kim SH, Hong CS, Jang AS, Park HS. The HLA DRB1*1501-DQB1*0602-DBP1*0501 haplotype is a risk factor for toluene diisocyanate-induced occupational asthma. Int Arch Allergy Immunol 2009;150:156–63.

7. Mapp CE, Beghè B, Balboni A, Zambonini G, Padoan M, Jovine L, Baricordi OR, Fabbrì LM. Association between HLA genes and susceptibility to toluene diisocyanate-induced asthma. Clin Exp Allergy 2000;30:651–6.

8. Ye YM, Kang YM, Kim SH, Kim CW, Kim HR, Hong CS, Park CS, Kim HM, Nahm DH, Park HS. Relationship between neurokinin 2 receptor gene polymorphisms and serum vascular endothelial growth factor levels in patients with toluene diisocyanate-induced asthma. Clin Exp Allergy 2006;36:1153–60.

9. Contopoulos-Ioannidis DG, Manoli EN, Ioannidis JP. Meta-analysis of the association of beta2-adrenergic receptor polymorphisms with asthma phenotypes. J Allergy Clin Immunol 2005;115:963–72.

10. Taylor DR, Kennedy MA. Beta-adrenergic receptor polymorphisms and drug responses in asthma. Pharmacogenomics 2002;3:173–84.

11. Hawkins GA, Tantisira K, Meyers DA, Ampleford EJ, Moore WC, Klangerman B, Liggett SB, Peters SP, Weiss ST, Bleecker ER. Sequence, haplotype, and association analysis of ADRbeta2 in a multicenter asthma case-control study. Am J Respir Crit Care Med 2006;174:1101–9.

12. Holloway JW, Yang IA. Beta2-Adrenergic receptor polymorphism and asthma: true or false? J Allergy Clin Immunol 2005;115:960–2.

13. Reilhäsus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the beta-2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993;8:334–9.

14. Borm PJ, Bast A, Zuiderveld OP. In vitro effect of toluene diisocyanate on Beta adrenergic and muscarinic receptor function in lung tissue of the rat. Br J Ind Med 1989;46:56–9.

15. McKay RT, Brooks SM. Effect of toluene diisocyanate on beta adrenergic receptor function. Biochemical and physiologic studies. Am Rev Respir Dis 1983;128:50–3.

16. Sitkauskienė B, Sakalauskas R. The role of beta(2)-adrenergic receptors in inflammation and allergy. Curr Drug Targets Inflamm Allergy 2001;1;128-130.

17. Cho SH, Oh SY, Bahn JW, Choi JY, Chang YS, Kim YK, Min KU, Kim YY. Association between bronchodilating response to short-acting beta-agonist and non-synonymous single-nucleotide polymorphisms of beta-adrenoceptor gene. Clin Exp Allergy 2005;35:1162–7.

18. Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM, Cooper DM, Fahy JV, Fish JE, Ford JG, Kraft M, Kunselman S, Lazarus SC, Lemanske RF Jr, Martin RJ, McLean DE, Peters SP, Silverman EK, Sorkness CA, Szefler SJ, Weiss ST, Yandava CN. Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma. Int Arch Allergy Immunol 2001;124:183–6.

19. Kim SH, Ye YM, Hur GY, Lee HY, Lee YK, Lee SH, Holloway JW, Park HS. Effect of beta2-adrenergic receptor polymorphism in asthma control of patients receiving combination treatment. Yonsei Med J 2009;50:182–8.

20. Park HS, Lee SK, Kim HY, Nahm DH, Kim SS. Specific immunoglobulin E and immunoglobulin G antibodies to toluene diisocyanate-human serum albumin conjugate: useful markers for predicting long-term prognosis in toluene diisocyanate-induced asthma. Clin Exp Allergy 2002;32:551–5.

21. Ye YM, Kim CW, Kim HR, Kim HM, Suh CH, Nahm DH, Park HS, Redlich CA, Wisnewski AV. Biophysical determinants of toluene diisocyanate antigenicity associated with exposure and asthma. J Allergy Clin Immunol 2006;118:885–91.

22. Wisnewski AV, Stowe MH, Cartier A, Liu Q, Liu J, Chen L, Redlich CA. Isocyanate vapor-induced antigenicity of human albumin. J Allergy Clin Immunol 2004;113:1178–84.

23. Burkett K, Graham J, McNeney B. hapassoc: Software for likelihood inference of trait associations with SNP haplotypes and other attributes. Journal of Statistical Software 2006;16:1–19.

24. Park HS, Shin ES, Lee JE. Genotypes and haplotypes of beta2-adrenergic receptor and parameters of the metabolic syndrome in Korean adolescents. Metabolism 2008;57:1064–70.

25. Kim SH, Oh SY, Oh HB, Kim YK, Cho SH, Kim YY, Min KU. Association of bet2-adrenoreceptor polymorphisms with nocturnal cough among atopic subjects but not with atopy and nonspecific bronchial hyperresponsiveness. J Allergy Clin Immunol 2002;109:630–5.

26. Coqueret O, Dugas B, Mencia-Huerta JM, Braquet P. Regulation of IgE production from human mononuclear cells by beta 2-receptor agonists. Clin Exp Allergy 1995;25:304–11.

27. Kay LJ, Rostami-Hodjegan A, Suvarna SK, Peachell PT. Influence of beta2-adrenoceptor gene polymorphisms on beta2-adrenoceptor mediated responses in human lung mast cells. Br J Pharmacol 2007;152:323–31.

28. Fedryk ER, Adawi A, Looney RJ, Phipps RP. Regulation of IgE and cytokine production by CAMP: implications for extrinsic asthma. Clin Immunol Immunopathol 1996;81:101–13.

29. McAlees JW, Sanders VM. Hematopoietic protein tyrosine phosphatase mediates beta2-adrenergic receptor-induced regulation of p38 mitogen-activated protein kinase in B lymphocytes. Mol Cell Biol 2009;29:675–86.

30. Liggett SB. The pharmacogenetics of beta 2-adrenergic receptors: relevance to asthma. J Allergy Clin Immunol 2000;105:S487–92.

31. Green SA, Turki J, Hall IP, Liggett SB. Implications of genetic variability of human beta 2-adrenergic receptor structure. Pulm Pharmacol 1995;8:1–10.

32. Kim WJ, Oh YM, Sung J, Kim TH, Huh JW, Jung H, Lee JH, Kim EK, Lee SM, Lee S, Lim SY, Shin TR, Yoon HJ, Kwon SY, Lee SD. Lung function response to 12-week treatment with combined inhalation of long-acting beta2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease. Lung 2008;186:381–6.

33. Llanes E, Quiralte J, López E, Sastre B, Chacártegui M, del Pozo V, Palomino P, Lahoz C, Cárdaba B. Analysis of polymorphisms in olfactory receptor gene polymorphism in patients with chronic obstructive pulmonary disease. Lung 2008;186:381–6.

34. Ramsay CE, Hayden CM, Tiller KJ, Burton PR, Hagel I, Palenque M, Redlich CA, Leyte FJ, LeSouef PN. Association of polymorphisms in the beta2-adrenoceptor gene with higher levels of parasitic infection. Hum Genet 1999;104:269–74.

35. Wass U, Belin L. Immunologic specificity of isocyanate-induced IgE antibodies in serum from 10 sensitized workers. J Allergy Clin Immunol 1989;83:126–35.

36. Hawn TR, Scholes D, Li SS, Wang H, Yang Y, Roberts PL, Stapleton AE, Janer M, Aderem A, Stamm WE, Zhao LP, Hooton TM. Toll-like receptor polymorphisms and susceptibility to urinary tract infections in adult women. PLoS One 2009;4:e5990.

37. Mapp CE. What is the role of genetics in occupational asthma? Eur Respir J 2009;33:459–60.